News | January 31, 2014

PICSO Impulse System Four Month Follow-Up Shows Infarct Size-Reduction

Miracor Medical PICSO Impulse System Clinical Trial Cath Lab

Coronary sinus pressure increase during two cycles of PICSO (clinical data from the Prepare PICSO study).


January 31, 2014 — Miracor Medical Systems completed four months’ follow-up of patients enrolled in the “Prepare RAMSES” clinical trial of PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) System. PICSO is designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). Interim data from early results indicate a strong trend towards a larger reduction in infarct for patients receiving the PICSO therapy in complement with primary PCI. A total of 30 patients have successfully enrolled in the clinical trial, with no device-related adverse events. 
 
The study is underway in several European centers with Principal Investigator Jan J. Piek, M.D., Ph.D., professor of interventional cardiology and director of the Heart Centre, Academic Medical Centre, University of Amsterdam. Miracor Medical is expanding PICSO’s CE marking throughout Europe. 
 
The Miracor PICSO Impulse System is designed to treat acute heart attack STEMI (ST-segment elevation myocardial infarction) patients in complement to coronary angioplasty. 
 
For more information: www.miracormedical.com

Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now